Breaking News

Sobi Enters Research Collaboration for Development of Gamifant in Sepsis

The EMBRACE Phase 2a study will adopt a precision immunotherapy approach for the treatment of sepsis driven by the IDS endotype.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sobi entered a research collaboration involving a new Phase 2a clinical trial for Gamifant (emapalumab) for the potential treatment of interferon-gamma (IFNγ)-driven sepsis (IDS).  IDS is a new endotype representing approximately 20 percent of sepsis patients and is characterized by detection of IFNγ (above lower limit of detection) and elevated levels of the chemokine CXCL9. The EMBRACE phase 2a study will investigate the potential of Gamifant (emapalumab) in treating a subgroup of sepsis...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters